This technology is a series of compounds that modulate ferroptosis for the treatment of excitotoxic and degenerative diseases.
Ferroptosis has been implicated in numerous pathologies, including Huntington’s disease, kidney disease, and traumatic brain injury. While modulation of ferroptosis is an attractive therapeutic strategy for the treatment of such conditions, existing compounds that inhibit this cell death pathway (ferrostatins) lack drug-like properties. As such, there remains a need for potent small molecule inhibitors of ferroptosis that possess enhanced molecular properties to allow for further drug development.
This technology describes a series of small-molecule ferroptosis modulators with enhanced drug-like properties over presently available ferrostatins. The compounds, which possess variable structures and moieties, effectively inhibit ferroptosis and reduce reactive oxygen species (ROS) in human cells. Importantly, the compounds may be administered alone or in combination with other therapeutic compounds for the treatment of degenerative diseases involving lipid peroxidation, as well as excitotoxic disorders involving oxidative cell death. The compounds and methods described by this technology may be further developed into therapeutics for the treatment or amelioration of various pathologies, including neurodegenerative diseases, stroke, and kidney disease.
IR CU17132
Licensing Contact: Beth Kauderer